IMUGENE LIMITED — AGM Information 2021

Nov 18, 2021

==> picture [178 x 76] intentionally omitted <==

A S X : I M U

IMUGENE AGM 2021

Experienced Management Team with Significant Clinical Development Expertise

==> picture [106 x 45] intentionally omitted <==

Imugene has a team with oncology clinical development experience

==> picture [72 x 72] intentionally omitted <==

Dr Rita Laeufle

CALIFORNIA, USA

Chief Medical Officer

• 27+ years of oncology experience in academia and industry

• Clinical development experience with bevacizumab, trastuzumab, abituzumab, CPIs and oncolytic viruses from Phase I – to post marketing Phase IV

• Former CMO at Oncolytics Biotech, Ex Genentech, Ex Hoffmann-La Roche, and Ex Novartis

==> picture [75 x 79] intentionally omitted <==

Dr Monil Shah

NEW JERSEY, USA Chief Business Officer

• 20+ years of oncology development experience in the pharmaceutical industry

• Former CDO at WindMIL, COO at Brooklyn

• ImmunoTherapeutics, and Head of Medical Affairs of ImmunoOncology at BMS

• Held senior roles at Novartis, Amgen, Fibrogen, and Celgene

==> picture [71 x 72] intentionally omitted <==

Dr Nick Ede

MELBOURNE, AUS Chief Technology Officer

• 25+ years peptide vaccine and drug development

• Former CEO Adistem and CEO of Mimotopes , VP Chemistry Chiron (now Novartis), Research Fellow CRC Vaccine Technology

==> picture [72 x 72] intentionally omitted <==

Dr Anthony Good

SYDNEY, AUS

Senior VP of Clinical Research

• 20+ years experience in global clinical development

• Integral to the development of significant new medicines including Viagra®, Lipitor®, and Somavert®

• Ex Pfizer Global Research and Development, Ex Covance Clinical Services

==> picture [72 x 72] intentionally omitted <==

==> picture [72 x 72] intentionally omitted <==

Amanda Seiz

Bonnie Nixon

ILLINOIS, USA

SYDNEY, AUS Senior Project Manager

Senior Director of Clinical Operations

• 10+ years of oncology clinical operations experience across Phase I – IV clinical trials

• 20+ years experience in global drug development

• 16+ years of clinical operations leadership experience in oncology at CROs, pharmaceutical and biotechnology companies

• Ex North America Study Manager at Genentech, Ex Roche Clinical Operations Australia

• Development experience with small molecules, checkpoint inhibitors, gene/cellular therapies and oncolytic viruses

• Ex Head of Clinical Operations WindMIL Therapeutics, Ex Astellas 2 Pharma, Ex MedImmune

Three Novel Technology Platforms

==> picture [106 x 45] intentionally omitted <==

==> picture [905 x 433] intentionally omitted <==

----- Start of picture text -----

onCARlytics
CF33 Oncolytic Virus B Cell Immunotherapy
CHECKvacc
VAXINIA
CF33-CD19 CAR T Combination Therapy “Armed” PD-L1 HER-Vaxx PD1-Vaxx
Parental Virus
Virus
TIGIT-Vaxx, PDL1-Vaxx, LAG3-Vaxx,
TIM3-Vaxx, VEGF-Vaxx, CTLA4-Vaxx etc
----- End of picture text -----

3

==> picture [59 x 59] intentionally omitted <==

HER-Vaxx

2021 YEAR IN REVIEW

==> picture [106 x 45] intentionally omitted <==

• HERIZON: Phase 2 Interim Results with positive OS

• HERIZON: Enrollment Completed

• Presentations at AACR, ASCO and ESMO World GI

• HERIZON: PFS endpoint reached

==> picture [183 x 32] intentionally omitted <==

==> picture [163 x 32] intentionally omitted <==

• HER-Vaxx patent granted in Japan

• 3 New Phase 2 Gastric Studies: neoHERIZON, nextHERIZON and neuHERIZON

• neoHERIZON: Neoadjuvant study in combination with Avelumab with clinical drug supply partnership with Merck KGaA & Pfizer

==> picture [631 x 178] intentionally omitted <==

==> picture [128 x 146] intentionally omitted <==

4

==> picture [59 x 59] intentionally omitted <==

2021 YEAR IN REVIEW

PD1-Vaxx

==> picture [194 x 39] intentionally omitted <==

• PD1-Vaxx FDA IND granted in the USA

==> picture [106 x 45] intentionally omitted <==

• IMPRINTER (Phase 1 Study): All 6 sites open in the USA and Australia

• Presentation at ESMO

• IMPRINTER (Phase 1 Study): Currently at the highest dose cohort

==> picture [127 x 40] intentionally omitted <==

==> picture [620 x 327] intentionally omitted <==

----- Start of picture text -----

Current Status
1st Patient Dosed 1st Patient Dosed Cohort 3 Cleared,
Cohort 1 Cleared Cohort 2 Cleared 1st Patient Dosed
Cohort 1 Cohort 2 RP2D & Expansion
Jan 2021 April 2021 Cohort 3
30 Nov 2020 Feb 2021 Opened
Ohio State University
(open)
Hackensack University
(open)
Macquarie University (open)
Chris O'Brien Lifehouse (open)
Cabrini Malvern (open)
Mayo Clinic
(open)
M I L E S T O N E S
----- End of picture text -----

5

==> picture [76 x 76] intentionally omitted <==

2021 YEAR IN REVIEW

CHECKvacc

==> picture [194 x 39] intentionally omitted <==

• CHECKvacc FDA IST IND granted in the USA

• • Presentation at AACR

==> picture [194 x 33] intentionally omitted <==

• CHECKvacc First Patient Dosed at COH

==> picture [106 x 45] intentionally omitted <==

==> picture [881 x 309] intentionally omitted <==

----- Start of picture text -----

COHORT | 3-6 PATIENTS
Identify:
COHORT | 3-6 PATIENTS Recommended Phase 2
Dose (RP2D)
RP2D Expansion
Metastatic Triple Negative COHORT | 3-6 PATIENTS
Based on:
Breast Cancer
12 Patients
COHORT | 3-6 PATIENTS • Safety
• Immunogenicity
COHORT | 3-6 PATIENTS • Tumour Response
Disease of need Potential target for Treatment responses to Potential for registration
Indication TNBC
immunotherapy Atezolizumab (JAMA in well-designed,
• 8-13 month survival Oncology, 5:74, 2019) randomised P2 study
for metastatic disease • Expresses PD1, FDA IND CHECKvacc: CF33-hNIS-aPDL1
with few treatments PD-L1 • 1st line: 24%;
2nd line: 6% N Part 1=18-24 ; Part 2=12
• Approved by FDA
8 March 2019 Location Single Center: COH
6
Admin Route Intratumoral (IT)
----- End of picture text -----

==> picture [106 x 45] intentionally omitted <==

2021 YEAR IN REVIEW

==> picture [76 x 76] intentionally omitted <==

onCARlytics

• Licensed a CD19 oncolytic virus invented by Professor Yuman Fong and Dr Saul Priceman from City of Hope to turn CAR-T therapy against solid tumours

==> picture [177 x 272] intentionally omitted <==

----- Start of picture text -----

1
4
2
3
----- End of picture text -----

• Exclusive strategic partnership to combine onCARlytics with Celularity’s allogeneic CAR-T, CyCART-19 immunotherapy for the treatment of solid tumors

• Strategic Collaboration to combine onCARlytics with Eureka Therapeutics ARTEMIS[®] T-Cell Therapy to accelerate therapy in solid tumours

==> picture [159 x 50] intentionally omitted <==

==> picture [96 x 55] intentionally omitted <==

==> picture [144 x 41] intentionally omitted <==

7

==> picture [960 x 450] intentionally omitted <==

----- Start of picture text -----

2021 Imugene Summary
S e p t e m b e r 2 0 2 1
S&P September
F e b r u a r y J u n e 2 0 2 1 J u l y 2 0 2 1 Quarterly Re-balance N o v e m b e r
2 0 2 1 2 0 2 1
CHECKvacc $95m Toal Imugene enters
PD1-Vaxx dose receives FDA IND Capital Raise ASX300 Strategic Partnership
escalates to &SPP with Eureka
cohort 2
A u g u s t
J u n e 2 0 2 1
M a y 2 0 2 1
2 0 2 1 O c t o b e r
Appointment of Dr
Licensed onCARlytics Monil Shah as the Strategic 2 0 2 1 N o v e m b e r 2 0 2 1
from City of Hope
Chief Business Partnership with CHECKvacc First HER-Vaxx Clinical Trial
invented by Dr Y Fong,
Dr S Priceman & Officer Celularity Patient Dosed Supply Partnership with
Merck KGaA Pfizer
Dr A Park
----- End of picture text -----

8

Milestones

==> picture [106 x 45] intentionally omitted <==

==> picture [16 x 16] intentionally omitted <==

estones
Technology	Milestone
onCARlytics	1st Patient Dosed
onCARlytics	FDA IND Clearance
PD1-Vaxx	Combination RP2D	Next 12-24 months
onCARlytics	GLP Toxicology Study
VAXINIA	1st Patient Dosed
onCARlytics	FDA Pre-IND Meeting
onCARlytics	GMP manufacturing for pre-clinical toxicology & Phase 1 study
VAXINIA	FDA IND Clearance
HER-Vaxx	Neo and Next HERIZON studies
PD1-Vaxx	Maximum Feasible Dose Identified
HER-Vaxx	OS Primary Endpoint
HER-Vaxx	Clinical Trial Supply Partnership with Merck KGaA and Pfizer
onCARlytics	Strategic Partnership with Eureka on autologous CD19 CART
CHECKvacc	TNBC IST 1st Patient Dosed
HER-Vaxx	PFS analysis data
onCARlytics	Strategic partnership with Celularity on allogenic CD19 CART
CHECKvacc	FDA IND Clearance

9

Financial Summary

Public Market Overview(17/11/21)
Share Price	A$0.54
52 week range	0.089 - 0.625
Market Capitalisation1	A$3.063B
Cash equivalents (30 Sept 21)	A$112.2M
Enterprise Value	A$2.946B
Top 5 Shareholders(as at November 2021)
Paul Hopper	6.96%
HSBC Custody Nominees (Australia)	5.98%
Richard Mann and Assoc.	5.35%
JP Morgan Nominees Australia Pty Limited	4.57%
Citicorp Nominees Pty Limited	3.67%

==> picture [106 x 45] intentionally omitted <==

==> picture [480 x 374] intentionally omitted <==

----- Start of picture text -----

Share Price Performance (last 12 months)
0.70
0.60
0.50
0.40
0.30
0.20
0.10
0
Nov-20 Dec-20 Jan-21 Feb-21 Mar-21 Apr-21 May-21 Jun-21 Jul-21 Aug-21 Sep-21 Oct-21 Nov-21
----- End of picture text -----

Note:

1. Market capitalisation calculations based on ordinary shares (5.673 bn) only and excludes the dilutive impact of options outstanding (0.558 bn)

10

==> picture [178 x 76] intentionally omitted <==

A S X : I M U

IMUGENE LIMITED www.imugene.com info@imugene.com